Previous 10 | Next 10 |
NOVATO, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D....
NOVATO, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced new long-term durability data fro...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this event. For further details see: Ultragenyx Pharmaceutical (RARE) Investor presentation- Slideshow
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Ultragenyx Pharmaceutical Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Ultragenyx Pharmaceutical inc (NASDAQ: RARE) Q3 2021 Earnings Call Nov 2, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical inc (RARE) Q3 2021 Earnings Call Tra...
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2021 Earnings Conference Call November 2, 2021 05:00 PM ET Company Participants Joshua Higa - Director of Investor Relations and Corporate Communications Emil Kakkis - President, Chief Executive Officer and Director Erik Harris - Executive Vice Preside...
Ultragenyx Pharmaceutical (NASDAQ:RARE): Q3 GAAP EPS of -$1.08 beats by $0.34. Revenue of $81.65M (+0.2% Y/Y) beats by $0.11M. Press Release 2021 Crysvita revenue in Ultragenyx territories now expected towards the upper end of the$180 million to $190 million range previously provided. Ca...
Third quarter 2021 total revenue of $81.6 million including Crysvita 1 revenue to Ultragenyx of $50.3 million 2021 Crysvita revenue in Ultragenyx territories 1 now expected towards the upper end of the$180 million to $190 million range previously provided...
NOVATO, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Tuesday, Novemb...
NOVATO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases, today announced that it has successfully screened and enr...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...